Last reviewed · How we verify

Ipsen SA — Portfolio Competitive Intelligence Brief

Ipsen SA (IPSEY) pipeline: 11 marketed, 0 filed, 11 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

IPSEY (OTC) 11 marketed 0 filed 11 Phase 3 4 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Iqirvo ELAFIBRANOR marketed Peroxisome Proliferator-activated Receptor Agonist [EPC] Metabolic 2024-01-01
Sohonos PALOVAROTENE marketed Retinoid [EPC] Retinoic acid receptor gamma Bone 2023-01-01
Bylvay ODEVIXIBAT marketed Ileal Bile Acid Transporter Inhibitor [EPC] Ileal sodium/bile acid cotransporter Infectious Disease 2021-01-01
OnaBoNT-A OnaBoNT-A marketed
BLI800 BLI800 marketed Other
Smecta Smecta marketed Other
EGb 761® (Tanakan®) EGb 761® (Tanakan®) marketed Herbal extract / Nootropic Neurology / Cardiovascular
Diosmectite (Smecta®) Diosmectite (Smecta®) marketed Adsorbent antidiarrheal agent Gastroenterology
Tigan® Tigan® marketed Dopamine antagonist antiemetic Dopamine receptor (D2) Gastroenterology / Antiemetic
AboBoNT-A AboBoNT-A marketed Botulinum neurotoxin type A SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology, Aesthetics, Pain Management
PEG 4000 (Forlax®) PEG 4000 (Forlax®) marketed Osmotic laxative Gastroenterology
Eziclen®/Izinova® Eziclen®/Izinova® phase 3 Osmotic laxative bowel cleanser Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bayer · 2 shared drug classes
  2. Taipei Veterans General Hospital, Taiwan · 2 shared drug classes
  3. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  4. Aboca Spa Societa' Agricola · 1 shared drug class
  5. Advanz · 1 shared drug class
  6. Ahmed M Maged, MD · 1 shared drug class
  7. Amsterdam UMC, location VUmc · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ipsen SA:

Cite this brief

Drug Landscape (2026). Ipsen SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ipsen. Accessed 2026-05-13.

Related